cox 189 has been researched along with plx4032 in 1 studies
| Studies (cox 189) | Trials (cox 189) | Recent Studies (post-2010) (cox 189) | Studies (plx4032) | Trials (plx4032) | Recent Studies (post-2010) (plx4032) |
|---|---|---|---|---|---|
| 163 | 49 | 47 | 1,657 | 103 | 1,587 |
| Protein | Taxonomy | cox 189 (IC50) | plx4032 (IC50) |
|---|---|---|---|
| Chain A, AKAP9-BRAF fusion protein | Homo sapiens (human) | 0.031 | |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.182 | |
| Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | 0.521 | |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0897 | |
| Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.03 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.36 | |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 1.5 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 1.5 | |
| Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | 0.0272 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blank, C; Brummer, C; Bruss, C; Faerber, S; Haferkamp, S; Herr, W; Kreutz, M; Lacroix, R; Renner, K | 1 |
1 other study(ies) available for cox 189 and plx4032
| Article | Year |
|---|---|
Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Diclofenac; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Energy Metabolism; Genetic Predisposition to Disease; Humans; Melanoma; Mitogen-Activated Protein Kinases; Mutation; Phenotype; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Signal Transduction; Skin Neoplasms; Time Factors; Vemurafenib | 2019 |